Trusted Resource for Clinical Trials, Protocols & Progress
The evolution of decentralized clinical trials and remote monitoring practices has brought virtual site visits to the forefront of regulatory oversight strategies. Both sponsors and clinical sites must now demonstrate compliance with Good Clinical Practice (GCP) while conducting remote visits that meet the expectations of authorities like the FDA, EMA, and ICH.
Click to read the full article.
Remote monitoring has become a foundational element of modern clinical trial oversight, particularly under risk-based monitoring (RBM) models. Regulatory agencies like the FDA, EMA, and ICH have endorsed risk-based approaches that emphasize critical data and processes, especially during remote and virtual site visits. One essential component of ensuring compliance and operational readiness in remote oversight is the use of a structured Pre-Visit Checklist.
Click to read the full article.
The shift from traditional on-site monitoring to virtual and hybrid site visits has become a strategic necessity in clinical trials. Sponsors, CROs, and regulatory agencies have embraced these models to ensure business continuity during disruptions like pandemics, but also to reduce cost and increase flexibility. However, this shift brings complexity in oversight models and operational documentation—especially Standard Operating Procedures (SOPs) and CAPA implementation.
Click to read the full article.
As virtual site visits become a mainstay in clinical trial oversight, proper documentation is crucial for inspection readiness. Regulatory agencies like the FDA, EMA, and ICH require that remote monitoring visits be supported with detailed, audit-ready reports—just like traditional on-site visits. However, virtual visit reports have their own set of expectations, including technology logs, access validations, and e-signature tracking.
Click to read the full article.
As clinical trials increasingly adopt decentralized and remote models, virtual site visits have become central to trial oversight. However, poorly planned technology infrastructure can lead to regulatory violations, data breaches, and failed inspections. The FDA, EMA, and ICH all expect sponsors to validate, document, and secure virtual visit tools in alignment with GCP and Part 11 requirements.
Click to read the full article.
As clinical trials increasingly adopt decentralized and remote models, virtual site visits have become central to trial oversight. However, poorly planned technology infrastructure can lead to regulatory violations, data breaches, and failed inspections. The FDA, EMA, and ICH all expect sponsors to validate, document, and secure virtual visit tools in alignment with GCP and Part 11 requirements.
Click to read the full article.
The shift toward remote clinical trial operations has made online site visits a standard practice. These visits—conducted virtually by Clinical Research Associates (CRAs) or monitors—play a critical role in verifying protocol adherence, reviewing source data, and assessing trial conduct. However, successful execution depends heavily on how well the site staff are prepared for these visits.
Click to read the full article.
The evolution of decentralized clinical trials has propelled virtual site visits from an emergency workaround during the COVID-19 pandemic to a long-term solution for remote oversight. However, regulatory acceptability of such visits depends on strict adherence to Good Clinical Practice (GCP), documented procedures, and quality systems supporting remote operations.
Click to read the full article.
Remote clinical trials have redefined how site monitoring is executed, with virtual site visits becoming a common alternative to traditional on-site interactions. While remote models offer flexibility and cost-efficiency, they introduce new complexities in determining the appropriate frequency of site oversight. Regulatory bodies such as the FDA, EMA, and ICH GCP emphasize that visit intervals must be justified by study risk, trial phase, and data quality trends—not by routine scheduling alone.
Click to read the full article.
As decentralized and hybrid clinical trial models become standard, video conferencing tools have emerged as a primary mechanism for conducting virtual site visits. These tools are used to facilitate discussions between site personnel and monitors, perform remote source data verification (rSDV), and document interactions for inspection readiness. However, not all video conferencing platforms are built to meet regulatory expectations set by FDA, EMA, and ICH GCP guidelines.
Click to read the full article.
